Acumen Pharmaceuticals (NASDAQ: ABOS) plans sale of 1,700 shares

Rhea-AI Filing Summary

A person associated with Acumen Pharmaceuticals, Inc. has filed a notice to sell 1,700 shares of common stock under Rule 144. The planned sale is through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of $3,379.50 based on the price used in the notice.

The 1,700 shares arose from the vesting of a restricted stock unit award on 01/06/2026, granted as part of the issuer’s equity compensation plan. The notice also states that the issuer has 60,573,425 shares of common stock outstanding, providing context for the size of the proposed sale.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common stock	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	1700	3379.50	60573425	01/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common stock	01/06/2026	Vesting of restricted stock unit award	Acumen Pharmaceuticals, Inc.			1700	01/06/2026	Granted as part of issuer equity compensation plan

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Acumen Pharmaceuticals (ABOS) disclose in this Form 144?

The notice discloses a proposed Rule 144 sale of 1,700 shares of Acumen Pharmaceuticals common stock through Merrill Lynch on the NASDAQ.

How many Acumen Pharmaceuticals (ABOS) shares are planned to be sold?

The filing covers a proposed sale of 1,700 shares of Acumen Pharmaceuticals common stock.

How were the 1,700 ABOS shares being sold acquired?

The 1,700 shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.

What is the aggregate market value of the ABOS shares to be sold?

The notice lists an aggregate market value of $3,379.50 for the 1,700 shares of Acumen Pharmaceuticals common stock to be sold.

On which exchange and through which broker will the ABOS shares be sold?

The proposed sale is to be executed on the NASDAQ through Merrill Lynch, located at 225 Liberty St, Floor 37, New York, NY 10281.

How many Acumen Pharmaceuticals common shares are outstanding according to the notice?

The notice states that there are 60,573,425 shares of Acumen Pharmaceuticals common stock outstanding.

Is the ABOS Form 144 sale related to a cash purchase?

No. The 1,700 shares were acquired via vesting of a restricted stock unit award, with the award granted as part of the issuer’s equity compensation plan rather than a cash purchase.